Psilocybin-Research.com Research. Clarity. Progress.
Preparing publication tracker
Psilocybin-Research.com Research. Clarity. Progress.

Psilocybin Research Publication Tracker

Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.

Database up to date Last update: Jul 3, 2026 01:22 UTC
Database evidence 3,975 indexed records
Indexed records 3,975 SQLite literature index
Published 3,210 Peer-reviewed / formal records
Preprints 478 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,554 64.3% Active
PubMed 302 7.6% Active
ClinicalTrials.gov 287 7.2% Active
OpenAlex 283 7.1% Active
PsyArXiv 216 5.4% Active
Crossref 157 3.9% Active
bioRxiv 142 3.6% Active
Publication timeline 3,072 dated records
3,072 records since 2020
Annual records Cumulative line
3,975Total Publications
3,834Psilocybin Records
553Psilocin Records
Search Matches
388Journals
66Research Topics
Current display No search or filter specified Showing the latest indexed records until a keyword search is submitted.
Page 16 of 199

CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial

The goal of this randomized placebo controlled trial is to compare the antidepressant effect of a single oral dose of psilocybin 25 mg compared to 1 mg in 100 patients with cancer related major depressive disorder. The main question it aims to answer is: The primary objective of this study is to evaluate the efficacy of a single 25 mg oral dose of psilocybin...

ClinicalTrials.gov 2026-04-12 Section for Affective Disorders; Northern Stockholm Psychiatry
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionClinical Trial Clinical Trial MDDpsilocybin 25 mg sod

Psilocybin acutely reduces low-frequency BOLD power and frequency-specific connectivity

Psilocybin and other serotonergic drugs acutely alter human brain function and large-scale connectivity as measured with BOLD fMRI, but whether these effects are frequency-specific remains unknown. We applied multitaper spectral and cross-spectral analyses to resting-state fMRI data from 28 healthy volunteers scanned multiple times acutely following oral psi...

bioRxiv 2026-04-12 Olsen AS, Larsen K, McCulloch DE, Ganz M, Madsen MK, Ozenne B, Knudsen GM, Rehman Nu, Fisher PM.
bioRxiv PREPRINT (not peer reviewed) psilocybinpsilocin Brain ImagingHealthy Volunteers Other

Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol

Prolonged grief disorder (PGD) affects approximately 10% of bereaved individuals and is now formally recognized in both the DSM-5-TR and ICD-11. Despite its prevalence, PGD often responds poorly to traditional therapeutic approaches. This manuscript outlines the protocol for an early-stage open-label feasibility trial investigating the use of psilocybin, a p...

Psychoactives 2026-04-12 Penberthy J. Kim, A. Wise Fatma, Cherup Nicholas, Penberthy J. Morgan, Mitchell Evaline, Burns Madeline, Akinlade Oluwafunmilayo, Chung David, Parmar Harshit, Singer Jonathan
Crossref Published psilocybin Brain ImagingRandomized Controlled TrialSafety Randomized Controlled Trial

The astrocytes in the prefrontal cortex contribute to the rapid antidepressant-like effects of psilocybin in the chronic restraint stress mouse model.

Psilocybin showed a rapid antidepressant response in several clinical trials, which offers new hope for treating depression. Astrocytes were associated with the etiology of depression and might contribute to the onset of psilocybin. In this study, we investigated the fast antidepressant effect of psilocybin and tested variations of GFAP (astrocytic markers) ...

Unknown journal 2026-04-11 Qiao YX, Dai W, Yao YS, Wei QQ, Yue CX, Yin YY, Li YF, Zhang LM.
Europe PMC Published psilocybinpsilocin DepressionMechanism of ActionBiomarkersMitochondrial FunctionClinical TrialAnimal StudyIn Vitro Study Clinical Trial Prefrontal CortexAstrocytes
Philosophical Psychology 2026-04-09 Rundquist Eric, Monasterio López Diego Nicolás, Oyarzo Alvarado Juan Jonathan, Carhart-Harris Robin, Pasquini Lorenzo, Vinson Erin, Girn Manesh, Ostrand Avery, Allison Kate, Kettner Hannes, Miller Catriona, Griffith Sydney, Gazzaley Adam, Rosati Andrea, Mitchell Jennifer
Crossref Published psilocybin General Other

Psilocybin elicits a conserved glucocorticoid-responsive gene signature across five 5-HT2A receptor-rich brain regions in rat.

ObjectivePsychedelics such as psilocybin are known for their hallucinogenic properties and have also been reported to produce long-lasting therapeutic effects in depression and possibly also other psychiatric disorders. Several lines of evidence suggest that psilocybin exerts its effects through activation of 5-HT2A receptors located postsynaptically to sero...

Unknown journal 2026-04-09 Veysi A, Atanasovski D, Ardalan M, Motamed N, Eriksson E.
Europe PMC Published psilocybin DepressionNeuroplasticityReceptor PharmacologyTranscriptomics Other BrainAmygdala

Sex-specific increased reactivity of the PVT and prolonged PVT→CeA circuit engagement following psilocin administration.

The psychedelic psilocybin has shown therapeutic potential, yet underlying neural mechanisms remain poorly understood. We investigated the impact of psilocin-the active metabolite of psilocybin-on basal activity and reactivity within the paraventricular nucleus of the thalamus (PVT) and PVT projections to central amygdala (CeA) in rats. Psilocin administrati...

Unknown journal 2026-04-09 Effinger DP, Hoffman JL, Quadir SG, Rollison CS, Toedt D, Echeveste Sanchez M, High MW, Hodge CW, Herman MA.
Europe PMC Published psilocybinpsilocin Mechanism of ActionEmotional Processing Other Paraventricular Hypothalamic NucleusNeurons

Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression.

BackgroundMajor depression is a prevalent condition among patients with life-threatening illnesses, such as cancer, and recent findings suggest that psilocybin may hold promising treatment potential. Contemporary trials of psilocybin generally employ a model that includes psychotherapeutic support consisting of preparation and integration sessions surroundin...

Unknown journal 2026-04-08 Morel NS, Stenbaek DS, Lundberg J, Beckman M.
Europe PMC Published psilocybin DepressionEnd-of-Life DistressRandomized Controlled Trial Randomized Controlled Trial HumansHallucinogens

Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.

In late spring 2024, CDC was alerted to an outbreak of poisoning potentially associated with eating Diamond Shruumz microdosing chocolate bars. Diamond Shruumz microdosing chocolate bars are edible products designed so that small doses of mushroom-derived psychoactive compounds and other psychoactive ingredients can be eaten in a presectioned serving. In res...

MMWR. Morbidity and mortality weekly report 2026-04-08 Rumph JT, Winquist A, Troeschel AN, Pulver S, Schnall AH, Ebersole J, Yeh M, Burt B, Federman SL, Klontz K, Dasenbrock C, Leahy HL, Brady S, Stuteville H, Patel K, Daniel J, Chang A
PubMed Published psilocin MicrodosingSafetyToxicity Other

Dissociating the Hallucinogenic and Neuroplastic Effects of Psilocybin

It is unclear how serotonin 2A receptors (5-HT2A Rs) in cortical layer 5 pyramidal neurons (L5 PyrNs) differentially contribute to psilocybin-induced hallucinations versus neuroplasticity. Here we show that psilocybin promotes synapse formation and maturation while accelerating the elimination of pre-existing synapses. Cell type-specific manipulation further...

bioRxiv 2026-04-08 Baker JJ, Kogan E, Ma S, Lu J, Zuo Y.
bioRxiv PREPRINT (not peer reviewed) psilocybin NeuroplasticityMechanism of ActionReceptor Pharmacology Other

Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder

The purpose of this study is to establish the safe administration of psilocybin in individuals with cocaine use disorder in terms of cardiovascular (e.g., heart rate) and subjective (e.g., mood) effects. The study's subject population consists of men and women between the ages of 21 and 55 from the Los Angeles area that meet criteria for cocaine use disorder...

ClinicalTrials.gov 2026-04-06 University of California, Los Angeles
ClinicalTrials.gov CLINICAL TRIAL psilocybin AddictionBrain ImagingAgingHealthcare WorkersSafety Other Cocaine Use DisorderPsilocybin

Altered States of Consciousness and the Subconscious Mind: A Comprehensive Comparative Review of Disciplines, Neurobiological Mechanisms, Clinical Applications, and Philosophical Frameworks - Including Life Between Lives and Transpersonal Hypnotherapy

Altered states of consciousness (ASC) represent a universal human capacity for accessing and transforming the subconscious mind, employed across cultures and millennia through diverse contemplative, somatic, pharmacological, ritual, and technological modalities. This comprehensive review synthesizes evidence from over 25 distinct disciplines spanning five cl...

Preprints.org 2026-04-06 Gallardo LM.
Europe PMC PREPRINT (not peer reviewed) psilocybin DepressionAnxietyPTSDNeuroplasticityBrain ImagingMechanism of ActionDefault Mode NetworkConsciousnessAgingRandomized Controlled TrialSystematic ReviewReview ArticleCase ReportTreatment-Resistant Depression Randomized Controlled Trial

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.

IntroductionAfter decades of regulatory marginalization, psychedelic compounds have reemerged as promising therapeutic tools in psychiatry, driven by unmet clinical needs in treatment-resistant mental disorders and by growing evidence of rapid and sustained effects on mood, cognition, and behavior.Areas coveredThis narrative review critically examined the cu...

Unknown journal 2026-04-06 Marazziti D, Gambini M, Gurrieri R, Russomanno G, Sità G, Pescini E, Digiuseppe FR, Mucci F.
Europe PMC Published psilocybin DepressionAnxietyPTSDAddictionMechanism of ActionClinical TrialReview ArticleTreatment-Resistant DepressionSafety Clinical Trial AnimalsHumans
Nature Mental Health 2026-04-05 Singleton S. Parker, Sevchik Brooke L., Lahey Analiese, Cuijpers Pim, Harrer Mathias, Jones Megan T., Nayak Sandeep M., Strain Eric C., Vandekar Simon N., Dworkin Robert H., Scott J. Cobb, Satterthwaite Theodore D.
Crossref Published psilocybin DepressionRandomized Controlled TrialMeta-AnalysisSystematic ReviewReview Article Randomized Controlled Trial

An international mega-analysis of psychedelic drug effects on brain circuit function.

Psychedelic drugs are re-emerging as promising scientific and clinical tools. However, despite a rapidly expanding literature on their therapeutic value, the neural mechanisms underlying psychedelic effects remain unclear. Resting-state functional magnetic resonance imaging studies of acute psychedelic effects, conducted independently by several research gro...

Unknown journal 2026-04-05 Girn M, Doss MK, Roseman L, Preller KH, Palhano-Fontes F, Pasquini L, Barrett FS, Mallaroni P, Mason NL, Timmermann C, McCulloch DE, Fisher PM, Winston BS, Moujaes F, Muller F, Liechti ME, Vollenweider FX, Ramaekers JG, Kuypers K, Araujo DB, Sporns O, Siegel J, Dosenbach N, Nutt DJ, Carhart-Harris RL, Stamatakis EA, Bzdok D.
Europe PMC Published psilocybin Brain ImagingMechanism of ActionAging Other BrainNerve Net

Catatonia Associated With First-Time Psilocybin Exposure: A Case Report.

In this case report, we highlight a 28-year-old male patient with predominantly retarded type of catatonia following a single incidence of psilocybin ingestion. This patient presented with a history of six months of mutism and inability to feed himself after consuming psilocybin for the first time. He did not have any history of psychiatric illness or substa...

Unknown journal 2026-04-04 Singh J, Mruthyunjaya P.
Europe PMC Published psilocybin AddictionBrain ImagingAgingCase Report Case Report

Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)

The goal of this clinical trial is to learn about the role that inducing neuroplasticity (the brain's ability to adapt and change) plays in the behavioral effects of psilocybin in people who have experienced a mild decline in emotional wellbeing. Researchers will compare different doses of psilocybin combined with midazolam or placebo to see what dose induce...

ClinicalTrials.gov 2026-04-02 University of Wisconsin, Madison
ClinicalTrials.gov CLINICAL TRIAL psilocybin NeuroplasticityBrain ImagingWellbeingEmotional ProcessingClinical Trial Clinical Trial PsilocybinPsilocybine

Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin

This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gai...

ClinicalTrials.gov 2026-04-02 University of Wisconsin, Madison
ClinicalTrials.gov CLINICAL TRIAL psilocybin NeuroplasticityWellbeingClinical TrialSafety Clinical Trial HealthyPsychedelic Experiences

Psilocybin and human longevity.

Psilocybin extends lifespan in aged mice, and this has prompted extensive media speculation about possible human longevity benefits. We examined mortality among prominent psychedelic personalities, researchers, and advocates who claimed psychedelic use (n = 11) and compared them with cancer (n = 12) and aging researchers (n = 5). All groups exceeded populati...

Unknown journal 2026-04-02 Lerer L.
Europe PMC Published psilocybin AgingLongevityAnimal Study Animal Study

Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants

N,N-dimethyltryptamine (DMT) is a classical psychedelic with similar effects like LSD or psilocybin. Preliminary evidence from case series and small open-label trials suggests that psychedelics may be promising candidates for the treatment of several pain-related diseases such as chronic pain, migraine, cluster headache or phantom limb pain. However, data fr...

ClinicalTrials.gov 2026-04-01 University Hospital, Basel, Switzerland
ClinicalTrials.gov CLINICAL TRIAL psilocybin Chronic PainHeadache / MigraineClinical TrialCase ReportHealthy Volunteers Clinical Trial HealthyIntravenous infusion of DMT

Live source coverage

3,975 indexed records across 8 active sources.

3,210Published
478Preprints
287Clinical trials
  1. Europe PMC 2,554 records · 64.3%
  2. PubMed 302 records · 7.6%
  3. ClinicalTrials.gov 287 records · 7.2%
  4. OpenAlex 283 records · 7.1%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 157 records · 3.9%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.